Donate
Family Conference
New Family

FYCOMPA® (perampanel) is indicated in patients with epilepsy aged 4 years and older for partial‑onset seizures (POS) with or without secondarily generalized seizures and adjunctive therapy for patients aged 12 years and older for primary generalized tonic‑clonic (PGTC) seizures.

See full prescribing information for complete boxed warning HERE:

WARNING: SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS

• Serious or life-threatening psychiatric and behavioral adverse reactions including aggression, hostility, irritability, anger, and homicidal ideation
and threats have been reported in patients taking FYCOMPA (5.1)
• Monitor patients for these reactions as well as for changes in mood, behavior, or personality that are not typical for the patient, particularly
during the titration period and at higher doses (5.1)
• FYCOMPA should be reduced if these symptoms occur and should be discontinued immediately if symptoms are severe or are worsening.

See full prescribing information

Related Posts

SOAR Webinar

SOAR Webinar

by | Apr 18, 2025

**At this time, the SOAR study has reached capacity for conference participation. However, there still may be opportunities for research participation at the family conference due to cancellations or addition of other opportunities. If you would like to be placed on a...

FDA Issues Recall On Clonazepam Orally Disintegrating Tablets

FDA Issues Recall On Clonazepam Orally Disintegrating Tablets

by | Dec 2, 2024

The Dup15q Alliance is aware of the recent release by the FDA regarding Clonazepam Orally Disintegrating Tablets USP by Endo USA due to potential product carton strength mislabeling. Ongoing investigation identified the possibility that the affected clonazepam product...

Recall – Vigabatrin for Oral Solution USP

Recall – Vigabatrin for Oral Solution USP

by | Dec 12, 2023

TOPIC: Vigabatrin for Oral Solution USP, 500 mg by InvaGen Pharmaceuticals: Recall - Due to Leaking Sachets AUDIENCE: Patient, Health Professional, Pharmacy, Pediatric, Neurology ISSUE: InvaGen Pharmaceuticals is recalling one lot, NB301030, of Vigabatrin for Oral...